• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Interpace Biosciences, Inc.

    2/10/22 5:14:38 PM ET
    $IDXG
    Medical/Dental Instruments
    Health Care
    Get the next $IDXG alert in real time by email
    SC 13G 1 singer_sc13g.htm INTERPACE BIOSCIENCES SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. ___) *

     

    Interpace Biosciences, Inc.

    (Name of Issuer)

     

    Common Stock, $.01 par value

    (Title of Class of Securities)

     

    46062X303

    (CUSIP Number)

     

    January 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐       Rule 13d-1(b)

    ☒       Rule 13d-1(c)

    ☐       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     
    CUSIP No. 46062X303Page 2 of 5

      

    1.

    Names of Reporting Persons

    I.R.S. Identification Nos. of above Persons (entities only).

     

    Douglas M. Singer

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)       ☐

    (b)       ☒     

     

    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    Sole Voting Power

     

    293,000

    6.

    Shared Voting Power

     

    - 0 -

    7.

    Sole Dispositive Power

     

    293,000

    8.

    Shared Dispositive Power

     

    - 0 -

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    293,000

    10.

    Check Box if the Aggregate Amount in Row 9 Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    6.98%

    12.

    Type of Reporting Person (See Instructions)

     

    IN

           

     

     
    CUSIP No. 46062X303Page 3 of 5

     

    Item 1. Name of Issuer
    (a)Name of Issuer:

    Interpace Biosciences, Inc.

    (b)Address of Issuer’s Principal Executive Offices:

    Morris Corporate Center 1, Building C

    300 Interpore Parkway

    Parsippany, NJ 07054

     

    Item 2. Name of Person Filing
      (a) Name:

    Douglas M. Singer

    (b)Address of Principal Business Office:

    9600 North 96th Street Unit 241

    Scottsdale, Arizona 85258

    (c)Citizenship:

    United States

    (d)Title of Class of Securities:

    Common Stock, $0.01 par value

      (e) CUSIP Number:

    46062X303

     

    Item 3. If this statement is filed pursuant to § 240.13d-1(b) or § 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)☐ Broker or dealer registered under Section 15 of the Act.
    (b)☐ Bank as defined in section 3(a)(6) of the Act.
    (c)☐ Insurance company as defined in section 3(a)(19) of the Act.
    (d)☐ Investment company registered under section 8 of the Investment Company Act of 1940.
    (e)☐ An investment adviser in accordance with § 240.13(d)-1(b)(1)(ii)(E).
    (f)☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F).
    (g)☐ A parent holding company or control person in accordance with § 240.13d-1(b)(ii)(G)
    (h)☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.
    (j)☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(J).

     

     
    CUSIP No. 46062X303Page 4 of 5

     

    Item 4. Ownership.

     

    All ownership information is as of February 7, 2022.

     

    (a)Amount Beneficially Owned: See Item 9 of Cover Sheet.
    (b)Percent of Class: See Item 11 of Cover Sheet.
    (c)Number of shares as to which the person has:
    (i)sole power to vote of to direct the vote: See Item 5 of Cover Sheet.
    (ii)shared power to vote or to direct the vote: See Item 6 of Cover Sheet.
    (iii)sole power to dispose or to direct the disposition of: See Item 7 of Cover Sheet.
    (iv)shared power to dispose or to direct the disposition of: See Item 8 of Cover Sheet.

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not Applicable.

     

    Item 8.Identification and Classification of Member of the Group

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10.Certification

     

    Not Applicable.

     
    CUSIP No. 46062X303Page 5 of 5

     

    Signatures

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

       
    Dated: February 8, 2022        /s/ Douglas M. Singer
                  Douglas M. Singer

     

     

     

     

     

    Get the next $IDXG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IDXG

    DatePrice TargetRatingAnalyst
    11/17/2021Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $IDXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Interpace Biosciences downgraded by HC Wainwright & Co.

      HC Wainwright & Co. downgraded Interpace Biosciences from Buy to Neutral

      11/17/21 6:16:49 AM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • HC Wainwright & Co. reiterated coverage on Interpace Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Interpace Biosciences with a rating of Buy and set a new price target of $9.00 from $6.00 previously

      4/9/21 7:22:39 AM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • HC Wainwright resumed coverage on Interpace Biosciences with a new price target

      HC Wainwright resumed coverage of Interpace Biosciences with a rating of Buy and set a new price target of $6.00 from $10.00 previously

      1/25/21 8:06:42 AM ET
      $IDXG
      Medical/Dental Instruments
      Health Care

    $IDXG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Interpace Biosciences Announces First Quarter 2025 Financial and Business Results

       ●Q1 Revenue of $11.5 million; a 13% increase year-over-year ●Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ●Q1 Thyroid test volume up 16% year-over-year to record levels ●Q1 Thyroid revenue of $8.0M; up 19% year-over-year to record levels ●Initiates Full Year 2025 Revenue Guidance of approximately $38 million    PARSIPPANY, NJ, May 08, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2025 and provided a business and financial update. First quarter Net Revenue was $11.5 million. Income from continuing operations in the first quarter

      5/8/25 4:05:00 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

      Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today announced that the Genetic Testing for Oncology (L39365) Local Coverage Determination (LCD) issued by the Medicare Administrative Contractor Novitas Solutions will go into effect, ending reimbursement for their PancraGEN® test. The Centers for Medicare & Medicaid Services (CMS) delayed implementation by 60 days earlier in the year and confirmed finalization of the LCD as of today, April 24, 2025. PancraGEN is a DNA-based diagnostic molecular test. It uniquel

      4/24/25 4:00:00 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results

       ●Q4 and FY Test volume increase 21% and 17% year-over-year ●Q4 and FY Volume, Revenue, and Profitability at all-time record levels     PARSIPPANY, NJ, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced preliminary financial and business results for the fiscal year and fourth quarter ended December 31, 2024. Fourth quarter Molecular Volume increased 21% year-over-year compared to Q4 2023, and 17% for the Full Year resulting in double-digit Q4 and YTD revenue growth. "The Company achieved record test volume, test revenue, income, and cash collections in Q4 and full year 2024," said Chris McCarthy, Chief Financial Office

      1/31/25 8:30:00 AM ET
      $IDXG
      Medical/Dental Instruments
      Health Care

    $IDXG
    Financials

    Live finance-specific insights

    See more
    • Interpace Biosciences Announces First Quarter 2022 Financial and Business Results

       ●Q1 Revenue of $10.4 million up 6% versus Prior Year ●Q1 Net Loss improved $2 million versus Prior Year ●Days Sales Outstanding (DSO) decreased by 27% PARSIPPANY, NJ, May 16, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2022 and provided a business and financial update. First quarter Net Revenue was $10.4 million, a 6% increase as compared to the same period of 2021. Our Net Loss in the first quarter of 2022 was $2.2 million, which represents an improvement of approximately $2 million from the prior year first quarter, driven by higher Net Revenues and lower oper

      5/16/22 4:15:00 PM ET
      $IDXG
      $TWST
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Interpace Biosciences Announces Third Quarter 2021 Financial and Business Results

       ●Q3 Revenue of $9.5 Million is a 15% Improvement versus Q3 2020 ●Year to Date Revenue of $30.5 Million Up 34% Versus Prior Year ●Second Consecutive Record Cash Collection Quarter ●Significantly Improved Liquidity with Comerica Bank $7.5 Credit Facility ●Entered into $8 million term loan with BroadOak Fund, V, L.P. ●Announcing New Proposed $30 Million Rights Offering PARSIPPANY, NJ, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended September 30, 2021 and provided a business and financial update. "2021 has been a dynamic and meaningful year in the evolution of Interpace

      11/10/21 4:05:00 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Interpace Biosciences Announces Second Quarter 2021 Financial and Business Results

       ●Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Company's Highest Revenue Quarter  ●Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating Expense Containment ●Restructuring Exceeding Full-Year Savings Expectations ●On Track to Exceed Full Year 2021 Revenue Growth of 35% ●Q2 Cash Collections in Excess of $11 Million Representing Highest Collection Quarter PARSIPPANY, NJ, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal quarter ended June 30, 2021 and provided a business and financial update. "Followin

      8/10/21 4:05:00 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care

    $IDXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Mccarthy Christopher converted options into 38,475 shares, increasing direct ownership by 463% to 46,791 units (SEC Form 4)

      4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)

      4/25/25 4:18:01 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Large owner 1315 Capital Ii, L.P.

      4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)

      10/15/24 7:00:31 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Large owner Ampersand 2018 Limited Partnership

      4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)

      10/15/24 7:00:05 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care

    $IDXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Interpace Biosciences, Inc.

      SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)

      10/16/24 4:35:44 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Interpace Biosciences, Inc.

      SC 13D/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)

      10/16/24 4:30:56 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Interpace Biosciences, Inc. (Amendment)

      SC 13G/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Subject)

      2/12/24 5:01:48 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care

    $IDXG
    Leadership Updates

    Live Leadership Updates

    See more
    • Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results

       ●2021 Full Year Net Revenue of $41.3 Million up 28% vs Prior Year; Fourth Quarter Net Revenue of $10.9 Million up 13% vs Prior Year  ●2021 Full Year Net Loss Improved $11.5 Million vs Prior Year ●Full year Cash Collections improved by 31% to $43.1 million and outpaced Revenue by nearly $2 million  PARSIPPANY, NJ, March 31, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fiscal year and fourth quarter ended December 31, 2021 and provided a business and financial update. "2021 has been a transformative year for Interpace," said Thomas Burnell, President and CEO. Burnell added, "The Company e

      3/31/22 4:15:00 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Interpace Biosciences Announces Appointment of Vijay Aggarwal, Ph.D. as New Director

      PARSIPPANY, NJ, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences , Inc. (OTCQX:IDXG) ("Interpace") a leader in enabling personalized medicine, is pleased to announce today that Vijay Aggarwal, Ph.D., has been appointed to the Interpace Board of Directors effective February 1, 2022. Dr. Aggarwal replaces Eric B. Lev, both designees of Ampersand 2018 Limited Partnership, a Series B Preferred stockholder of the Company. Dr. Aggarwal has over thirty years of experience in both pharmaceutical services and clinical diagnostics. In addition to serving as Managing Partner of The Channel Group, Dr. Aggarwal provides strategic advisory services to companies with operations or investments in

      1/27/22 4:05:00 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care

    $IDXG
    SEC Filings

    See more
    • SEC Form 10-Q filed by Interpace Biosciences, Inc.

      10-Q - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)

      5/8/25 4:28:33 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Interpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)

      5/8/25 4:25:28 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care
    • Interpace Biosciences, Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits

      8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)

      4/30/25 7:31:33 PM ET
      $IDXG
      Medical/Dental Instruments
      Health Care